1. Home
  2. FGNX vs SONN Comparison

FGNX vs SONN Comparison

Compare FGNX & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FGNX
  • SONN
  • Stock Information
  • Founded
  • FGNX 1932
  • SONN N/A
  • Country
  • FGNX United States
  • SONN United States
  • Employees
  • FGNX N/A
  • SONN N/A
  • Industry
  • FGNX Property-Casualty Insurers
  • SONN Biotechnology: Pharmaceutical Preparations
  • Sector
  • FGNX Finance
  • SONN Health Care
  • Exchange
  • FGNX Nasdaq
  • SONN Nasdaq
  • Market Cap
  • FGNX 25.2M
  • SONN 21.4M
  • IPO Year
  • FGNX N/A
  • SONN N/A
  • Fundamental
  • Price
  • FGNX $3.84
  • SONN $4.90
  • Analyst Decision
  • FGNX Strong Buy
  • SONN Strong Buy
  • Analyst Count
  • FGNX 1
  • SONN 1
  • Target Price
  • FGNX $8.00
  • SONN $20.00
  • AVG Volume (30 Days)
  • FGNX 1.0M
  • SONN 478.9K
  • Earning Date
  • FGNX 11-19-2025
  • SONN 08-13-2025
  • Dividend Yield
  • FGNX N/A
  • SONN N/A
  • EPS Growth
  • FGNX N/A
  • SONN N/A
  • EPS
  • FGNX 2.41
  • SONN N/A
  • Revenue
  • FGNX $24,184,000.00
  • SONN $1,000,000.00
  • Revenue This Year
  • FGNX N/A
  • SONN $5,376.22
  • Revenue Next Year
  • FGNX N/A
  • SONN N/A
  • P/E Ratio
  • FGNX $1.59
  • SONN N/A
  • Revenue Growth
  • FGNX 24.03
  • SONN 1689.52
  • 52 Week Low
  • FGNX $3.35
  • SONN $1.08
  • 52 Week High
  • FGNX $41.25
  • SONN $19.30
  • Technical
  • Relative Strength Index (RSI)
  • FGNX N/A
  • SONN 53.87
  • Support Level
  • FGNX N/A
  • SONN $3.52
  • Resistance Level
  • FGNX N/A
  • SONN $4.18
  • Average True Range (ATR)
  • FGNX 0.00
  • SONN 0.48
  • MACD
  • FGNX 0.00
  • SONN -0.03
  • Stochastic Oscillator
  • FGNX 0.00
  • SONN 68.28

About SONN Sonnet BioTherapeutics Holdings Inc.

Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.

Share on Social Networks: